Meeting
2020 ASCO Virtual Scientific Program
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
Authors
Hong-Fei Gao
Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China, Guangzhou, China
Hong-Fei Gao , Zhiyong Wu , Ying Lin , Xiangyang Song , Yin Cao , Zhenzhen Liu , Qian-Jun Chen , Liulu Zhang , Ci-Qiu Yang , Mei Yang , Teng Zhu , Jieqing Li , Fei Ji , Min-Yi Cheng , Kun Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT03140553
Citation
J Clin Oncol 38: 2020 (suppl; abstr 585)
DOI
10.1200/JCO.2020.38.15_suppl.585
Abstract #
585
Poster Bd #
77
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial.
First Author: J. D. Zubkus
First Author: Nicholas Patrick McAndrew
Poster
2022 ASCO Annual Meeting
Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA).
First Author: Atara Isaiah Ntekim
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial.
First Author: Liulu Zhang